CompletedPhase 2NCT01266447
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Charles Kunos, MD,PHDNRG Oncology
- Intervention
- Filgrastim(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2011 – 2016
Study locations (30)
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Florida Hospital Orlando, Orlando, Florida, United States
- Memorial University Medical Center, Savannah, Georgia, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
- Memorial Medical Center, Springfield, Illinois, United States
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
- Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01266447 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital